Drug intelligence / Profile preview

Surfaz-SN

Development stage: Unknown
Lead developer: Franco-Indian Pharmaceuticals
Modality: Small Molecules
Administration: Topical

Overview

Surfaz-SN is a topical combination cream developed and marketed by Franco-Indian Pharmaceuticals for the treatment of mixed skin infections. It contains beclomethasone dipropionate, a corticosteroid that alleviates inflammation, itching, and redness; clotrimazole, a broad-spectrum imidazole antifungal that disrupts fungal cell membrane integrity; and neomycin sulphate, an aminoglycoside antibiotic that targets bacterial protein synthesis. This triple-action formulation is specifically indicated for dermatological conditions where bacterial or fungal infections are present alongside inflammatory symptoms.

Brand names: Surfaz-SNSurfaz SN Cream
Other names: beclomethasone + clotrimazole + neomycin

Targets

CYP51A1 (Sterol 14α-demethylase)Bacterial RibosomeGR (Glucocorticoid receptor)

Beyond the preview

Go deeper on Surfaz-SN.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Surfaz-SN.

Explore the full profile